599-P: The Effects of Cardiac Rehabilitation and Exercise Training in Hospital among Patients of Diabetic Cardiovascular Disease with Sarcopenic Obesity

Abstract

Background: The patients of type 2 diabetes have known to have a higher chance of having Sarcopenic obesity, in which the increase of body fat and the decrease of extremity muscles is observed. A high level of lower-limb muscle has been known to associated with a lower risk of cardiovascular mortality in patients with cardiovascular diseases. The effects of cardiac rehabilitation (CR) on the patients of diabetic cardiovascular disease with sarcopenic obesity has not been well known. The aim of this study was to examined the change of body compositions and of lower-limb muscle strength between diabetic (DM) and nondiabetic (Non-DM) cardiovascular disease patients during CR. Methods: A total of 82 male patients were assigned to the study who discharged from the acute-phase treatments for ischemic heart disease (IHD) or heart failure (HF) (DM group; n=33, Non-DM group; n=49). The body compositions and the lower-limb muscle strength were evaluated before and after CR twice a week for 5 months and analyzed retrospectively. Results and Conclusions: The DM group before performing the CR showed significant increase in body fat and decrease in lower-limb muscle strength, compared with the non-DM group (p<0.05). The effects of increasing lower-limb muscle strength after CR were observed in both DM and non-DM groups (n,c). Moreover, HF patients had weaker lower-limb muscle strength before CR than IHD patients (p<0.05) and it was even weaker among the DM. However, after CR, the increasing effects of lower-limb muscle tended to be stronger in the DM group. These data showed that the patients with diabetic cardiovascular disease with sarcopenic obesity have a chance to have increase of the lower-limb muscle strength after CR as well as that of nondiabetic cardiovascular disease. A lower-limb muscle might be a new scale and a therapeutic target in patients with cardiovascular disease. Disclosure Y. Kayama: None.